Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
11.10
Dollar change
+0.09
Percentage change
0.82
%
Index- P/E- EPS (ttm)-24.00 Insider Own38.80% Shs Outstand6.50M Perf Week-9.09%
Market Cap72.15M Forward P/E- EPS next Y-13.36 Insider Trans0.00% Shs Float3.98M Perf Month-5.77%
Income-156.09M PEG- EPS next Q-2.23 Inst Own21.77% Short Float0.38% Perf Quarter50.61%
Sales0.00M P/S- EPS this Y10.26% Inst Trans0.92% Short Ratio0.45 Perf Half Y35.04%
Book/sh34.72 P/B0.32 EPS next Y-46.76% ROA-38.65% Short Interest0.02M Perf Year-10.08%
Cash/sh23.36 P/C0.48 EPS next 5Y- ROE-52.96% 52W Range6.07 - 14.00 Perf YTD45.67%
Dividend Est.- P/FCF- EPS past 5Y-120.38% ROI-50.33% 52W High-20.71% Beta1.26
Dividend TTM- Quick Ratio15.22 Sales past 5Y-25.00% Gross Margin- 52W Low82.87% ATR (14)0.48
Dividend Ex-Date- Current Ratio15.22 EPS Y/Y TTM30.37% Oper. Margin0.00% RSI (14)40.03 Volatility4.07% 4.13%
Employees49 Debt/Eq0.38 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price36.00
Option/ShortNo / Yes LT Debt/Eq0.37 EPS Q/Q76.03% Payout- Rel Volume0.26 Prev Close11.01
Sales Surprise- EPS Surprise55.71% Sales Q/Q- EarningsMar 21 AMC Avg Volume33.40K Price11.10
SMA20-7.21% SMA50-3.99% SMA20016.75% Trades Volume8,600 Change0.82%
Date Action Analyst Rating Change Price Target Change
Nov-01-22Downgrade Truist Buy → Hold $16 → $6
Nov-01-22Downgrade Cowen Outperform → Market Perform
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Mar-27-24 12:00PM
Mar-21-24 10:52PM
05:00PM
Jan-18-24 12:28PM
Jan-16-24 08:00AM
10:52AM Loading…
Dec-13-23 10:52AM
10:51AM
Dec-05-23 05:00PM
Nov-13-23 05:00PM
Nov-06-23 07:00AM
Aug-31-23 09:35AM
Aug-14-23 07:00AM
Jun-26-23 04:38PM
May-11-23 07:00AM
Mar-31-23 07:00AM
07:57AM Loading…
Mar-22-23 07:57AM
Feb-17-23 07:04AM
Jan-31-23 05:00PM
Jan-09-23 12:30PM
07:00AM
Dec-13-22 09:35AM
Dec-09-22 09:35AM
Dec-08-22 11:04AM
07:00AM
Nov-14-22 04:07PM
Nov-08-22 07:00AM
Oct-31-22 10:40AM
08:52AM
07:00AM
Oct-18-22 07:00AM
07:20AM Loading…
Sep-19-22 07:20AM
Sep-09-22 07:00AM
Sep-06-22 07:00AM
Aug-12-22 07:00AM
Jul-12-22 08:21AM
Jul-11-22 05:28PM
May-27-22 07:00AM
May-18-22 07:00AM
May-16-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 07:00AM
Nov-15-21 07:00AM
07:00AM
Nov-10-21 11:28AM
Nov-08-21 08:05AM
Sep-16-21 07:00AM
Sep-15-21 04:27PM
Sep-13-21 07:00AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-19-21 02:34PM
Jun-21-21 10:06AM
Jun-01-21 07:00AM
May-13-21 07:00AM
Apr-29-21 08:45AM
Apr-27-21 07:00AM
Apr-12-21 07:18AM
Mar-23-21 05:00PM
Mar-19-21 04:25PM
Mar-18-21 08:26PM
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.